HIMSS Updated CPHIMS Exam Questions and Answers by gaia

Acceptance testing (User Acceptance Testing/UAT) is the testing phase most likely to identify an inability to process prescriptions that existed before cutover , because UAT validates that the solution supports real operational workflows and business requirements under conditions that mirror production use. A key go-live risk in pharmacy system replacement is data conversion and continuity of care : prescriptions entered in the legacy system prior to cutover must be accessible and actionable in the new environment (e.g., visible in work queues, eligible for verification, dispensing, labeling, adjudication, and documentation). In well-designed acceptance testing, users execute scripted scenarios that include “pre-cutover” items—converted orders, historical prescriptions, and in-flight work—specifically to confirm that the new system can safely continue processing without interruption.

By comparison, unit testing focuses on individual components and would not validate end-to-end prescription processing across converted legacy data. System integration testing emphasizes interfaces between systems (e.g., EHR-to-pharmacy, claims, automation) but may not adequately validate business readiness with converted pre-cutover prescriptions unless explicitly included. Regression testing checks that changes did not break previously working functions, but it is not the primary phase for validating cutover continuity. Therefore, acceptance testing is the best answer.

Integration and interoperability most positively impact clinicians by reducing redundant work , strengthening clinical decision support (CDS) , and enabling outcomes tracking across settings—making D the best answer. When systems interoperate, clinicians can access relevant patient information (problems, medications, allergies, labs, imaging summaries, discharge plans) without re-entering or re-requesting the same data. This reduces duplicate documentation, repeated tests, and time-consuming reconciliation tasks, freeing clinician time for direct patient care and improving workflow efficiency.

Interoperability also improves the validity and usefulness of CDS because decision support depends on complete, timely, and accurate data. If key data are missing—outside medications, recent lab results, or diagnoses from another facility—alerts and recommendations may be inappropriate, leading to alert fatigue or unsafe decisions. Better data integration increases CDS reliability and relevance.

Finally, interoperable data supports tracking clinical outcomes over time and across care transitions (inpatient, outpatient, specialty, community services). This helps clinicians monitor disease control, follow-up completion, readmissions, and adherence to evidence-based care, which supports quality improvement and value-based care goals. While standardized terminologies (A) and clearer documentation (C) contribute, the most direct clinician-facing benefits are captured in option D .

Fully customizing a healthcare information system to match an organization’s current workflow can create long-term operational risk because extensive customization often becomes tightly coupled to a specific vendor version and technical architecture. As vendors release upgrades, patches, and new features (often driven by patient-safety improvements, interoperability requirements, cybersecurity fixes, and regulatory updates), heavily customized environments typically require significant rework, retesting, and validation to ensure the custom components still function correctly. This can delay or effectively block timely upgrades, leaving the organization on older versions that may lack critical security patches or updated functionality.

While customization may reduce training needs in the short term by preserving familiar workflows (making option A an advantage), the upgrade burden is a classic downside: custom code, custom interfaces, and non-standard configurations increase maintenance complexity and can break during version changes. Over time, this can raise total cost of ownership and reduce agility, especially when the organization needs to adopt new standards, integrate additional systems, or support new care models. Therefore, the most direct and strategically significant disadvantage listed is the inability (or practical difficulty) of implementing future system upgrades, captured best by option C .

The central interoperability challenge in transitions of care across different organizations is patient matching —ensuring that incoming clinical information is accurately linked to the correct individual. This is best captured by patient identity integrity , which refers to the correctness, completeness, and consistency of a patient’s identity data across systems so records are not mismatched (overlay) or split/duplicated. When identity integrity is weak, care teams may receive incomplete histories, allergies, medications, or problem lists—or, worse, information for the wrong person—creating direct patient-safety risk and undermining continuity of care.

While patient demographic data (name, DOB, address, phone) is used as input for matching, demographics alone are not the “challenge”—the challenge is maintaining integrity and reliably matching across systems with variations, missing fields, typos, name changes, and differing registration workflows. A unique patient identifier could help, but in real-world cross-provider exchange it is often not universally available or consistently used across all participants. An enterprise master patient index (EMPI) is a tool that supports matching within an enterprise or network, but the broader interoperability problem remains the integrity and accuracy of identity across boundaries. Therefore, overcoming patient identity integrity issues is essential to ensure the right patient receives the right care.